Background: Previously, we reported the efficacy of Lichtena® – a phytocosmetic cream product – in atopic dermatitis (AD). Later, fraudulent triamcinolone acetonide (TACA) was detected at low doses (16–40 µg/g) in Lichtena. This suggested that TACA may be effective at much lower concentrations than used in commercial products (1,000 µg/g). Objectives: To investigate the efficacy in AD of low-dose TACA in Lichtena compared to plain Lichtena. Methods: Fourteen patients presenting symmetrical lesions of AD were treated for 1 month with Lichtena plus 25 µg/g TACA (= verum) and plain Lichtena (= placebo). The severity of the lesions was assessed by the Severity Scoring of Atopic Dermatitis (SCORAD) on days 0 (= baseline), 7, 14 and 28. Results: Already after 1 week of treatment, significant SCORAD differences to baseline were observed comparing verum- and placebo-treated areas. No improvement was observed using plain Lichtena. Conclusions: TACA displayed a significant improvement of AD at doses up to 40 times lower than in commercial products.

Keywords:
Atopic dermatitis, Lichtena®, Low-dose corticosteroids, Extemporaneous compounding, Phytocosmetic, Severity Scoring of Atopic Dermatitis (SCORAD)
1.
Breuer K, Braeutigam M, Kapp A, Werfel T: Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology 2004;209:314–320.
2.
Kagi MK: Leukotriene receptor antagonists – A novel therapeutic approach in atopic dermatitis? Dermatology 2001;203:280–283.
3.
Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, Schachner LA, Sidbury R, Whitmore SE: Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association ‘Administrative Regulations for Evidence-Based Clinical Practice Guidelines’. J Am Acad Dermatol 2004;50:391–404.
4.
Ernst E: The usage of complementary therapies by dermatological patients: A systematic review. Br J Dermatol 2000;142:857–861.
5.
Ernst E: Adverse effects of herbal drugs in dermatology. Br J Dermatol 2000;143:923–929.
6.
Report on the enquiry into fraudulent practice in the treatment of skin disease. A report of the All Party Parliamentary Group on Skin. London, December 1999.
7.
Keane FM, Munn SE, du Vivier AWP, Taylor NF, Higgins EM: Analysis of Chinese herbal creams prescribed for dermatological conditions. BMJ 1999;318:563–564.
8.
Bircher AJ, Surber C: Unregulated alternative medicine – Focus on. J Drugs Dermatol 2003;2:58–61.
9.
Grassi A, Palermi G, Paradisi M: Study of tolerance and efficacy of cosmetic preparations with lenitive action in atopic dermatitis in children. Clin Ther 2000;151:77–80.
10.
Hrubes B: Wirksamkeit und Verträglichkeit von Lichtena A.I. bei atopischer Dermatitis; dissertation, Medizinische Fakultät Universität Basel, Basel, 2001.
11.
Bircher AJ, Hauri U, Niederer M, Hohl C, Surber C: Stealth triamcinolone acetonide in a phytocosmetic cream. Br J Dermatol 2002;146:531–532.
12.
Hanifin J, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980;suppl 92:44–47.
13.
Long CC, Mills CM, Finlay AY: A practical guide to topical therapy in children. Br J Dermatol 1998;138:293–296.
14.
Severity Scoring of Atopic Dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23–31.
15.
Ling MR: Extemporaneous compounding – The end of the road? Dermatol Clin 1998;16:321–327.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.